Global Monocyte Activation Test Market Set to Soar with Regulatory Backing & Biologics Boom
The Monocyte Activation Test Market is witnessing remarkable growth, driven by surging demand for non-animal pyrogen testing methods, evolving global regulatory landscapes, and the rapid development of biologics. As regulatory agencies across Europe, North America, and Asia-Pacific pivot toward in vitro testing methods, industry players are actively adopting the MAT platform, establishing it as a cornerstone of biologics safety and compliance.
According to recent analysis, “The monocyte activation test (MAT) market size was valued at USD 595 million in 2024 and is expected to reach USD 1956.47 million by 2032, growing at a CAGR of 16.07% over 2025-2032.”
Get a Free Sample Report of Monocyte Activation Test Market@ https://www.snsinsider.com/sample-request/7483
Growth Driver: Rising Global Regulatory Acceptance and Biologics Proliferation
A key catalyst fueling the Monocyte Activation Test Market is the growing global shift towards ethical and standardized non-animal testing protocols. Regulatory agencies such as the European Medicines Agency (EMA), Brazil’s ANVISA, and South Korea’s MFDS have endorsed MAT as an alternative to Rabbit Pyrogen Tests (RPT). In February 2025, EMA released an updated reflection paper reinforcing MAT’s leadership as the preferred method for detecting pyrogens in biotherapeutics.
Furthermore, global biologics production continues its sharp upward trend, with injectable biologics manufacturing expanding by over 8.7% in 2023. Pyrogen testing for these products is vital, and MAT’s relevance is further strengthened due to its reproducibility, human-specific results, and regulatory alignment. Manufacturers like Lonza and FUJIFILM Wako have responded with innovations such as the PyroCell MAT system and LumiMAT kits, accelerating industry-wide adoption.
Market Dynamics
Drivers:
Rising Regulatory Push: Agencies like the FDA, EMA, and ICCVAM are backing MAT in response to ethical mandates and scientific reliability. ICCVAM’s 2023 report indicated that 65% of drug manufacturers plan to integrate MAT into their QC operations.
Expansion in Biologics Pipeline: With 9,000 biologics under development globally in 2024, many of which are injectables, the need for rapid, reproducible pyrogen testing has surged.
Pharma Investment & Technology Integration: Leading companies such as Johnson & Johnson and AstraZeneca ramped up R&D budgets in 2023 to enhance biologics safety—spurring MAT-based innovation.
Restraints:
Validation Costs and Technical Complexity: MAT validation costs ranging between USD 150,000 and USD 500,000 per product batch pose challenges, especially for small-to-midsize manufacturers.
Global Regulatory Fragmentation: While the EU and parts of Asia have embraced MAT, several countries in the Middle East and Africa still mandate traditional animal-based pyrogen tests.
Infrastructure & Skill Gaps: A 2022 WHO report found that only 20% of low-to-mid-income countries possess the facilities and trained personnel to implement MAT protocols.
Segment Analysis
By Product:
The MAT Kits segment held a 65.7% share in 2024 and will remain dominant due to the scalability, automation compatibility, and ease of integration into biologics production pipelines. Meanwhile, reagents are growing at the highest CAGR as demand intensifies for customized solutions in specialized applications, especially in vaccine and cell therapy development.
By Application:
The drug development segment leads the Monocyte Activation Test Market due to stringent sterility regulations and the growing volume of biologic therapeutics. The vaccine development segment is the fastest-growing, fueled by increased vaccine production and a post-pandemic focus on safety and efficacy through non-animal testing.
By Source:
PBMC-based MAT dominated the market in 2024 because of its accessibility, cost-effectiveness, and high compatibility with human immune responses. However, cell line-based MAT is gaining traction for its reproducibility, scalability, and automation-friendly nature, key features for large-scale biologics and vaccine manufacturing environments.
By End-use:
The pharmaceutical industry held 58.3% of the market in 2024. The need to comply with updated pyrogen testing mandates for injectable drugs has made MAT a go-to standard. The biotechnology sector is the fastest-growing segment, driven by advanced therapies including gene and cell therapies that require sensitive, human-relevant pyrogen tests.
Regional Insights
North America is the global leader in the Monocyte Activation Test Market, with the U.S. alone reaching USD 170.84 million in 2024 and projected to hit USD 522.48 million by 2032, at a CAGR of 15.06%. Strong regulatory support, high biologics production, and increasing automation in drug QC labs are key factors propelling regional growth.
Europe ranks second, with wide MAT acceptance driven by the 3Rs (Replacement, Reduction, Refinement) principles. Countries like Germany, France, and the U.K. are spearheading MAT adoption through R&D investments and government-supported regulatory harmonization.
Asia Pacific is the fastest-growing region, fueled by booming pharmaceutical manufacturing in China and India, rising biologics R&D, and government initiatives to modernize QC infrastructures. Japan and South Korea are also emerging as MAT innovation hubs due to advanced regulatory alignment and strong domestic biotech pipelines.
Key Players in the Monocyte Activation Test Market:
Lonza Group
FUJIFILM Wako
Charles River Laboratories
Bio-Rad Laboratories
Merck KGaA
Thermo Fisher Scientific
Hyglos GmbH
Seikagaku Corporation
MAT BioTech
Eurofins Scientific
Buy a Single-User PDF of Monocyte Activation Test Market Analysis & Outlook Report 2024-7483@ https://www.snsinsider.com/checkout/7483
Recent Developments:
June 2024: FUJIFILM Wako launched LumiMAT, a cell line-based MAT kit using luciferase reporting, offering results in just 5 hours with higher stability.
October 2023: Lonza unveiled its PyroCell MAT Rapid System, reducing test times from two days to just two hours, a major efficiency boost for biologics QC.
Conclusion
The Monocyte Activation Test Market is poised for transformative growth, buoyed by ethical imperatives, regulatory mandates, and technological advancements. With the increasing demand for safe, animal-free, and scalable pyrogen detection methods, MAT is quickly becoming the global gold standard. Stakeholders in biologics, pharmaceuticals, and vaccines are embracing MAT not only to comply with international standards but also to enhance testing efficiency, ensure product safety, and support sustainable innovation.
As regulatory landscapes evolve and MAT-specific technologies continue to advance, this market is set to become a linchpin in the future of quality control in biologics and injectable therapeutics.
Read Our Other Report
About Us:
SNS Insider is one of the leading market research and consulting agencies that dominates the market research industry globally. Our company’s aim is to give clients the knowledge they require in order to function in changing circumstances. In order to give you current, accurate market data, consumer insights, and opinions so that you can make decisions with confidence, we employ a variety of techniques, including surveys, video talks, and focus groups around the world.
Contact Us:
Jagney Dave – Vice President of Client Engagement
Phone: +1-315 636 4242 (US) | +44- 20 3290 5010 (UK)
Email: [email protected]
